SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 7, 2017, Eric H. Bjerkholt, Executive Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary of Sunesis Pharmaceuticals, Inc. (the “Company”), informed the Company of his resignation from all of his positions at the Company effective as of April 27, 2017, in order to pursue another opportunity. Mr. Bjerkholt will remain an employee of the Company through April 27, 2017. Mr. Bjerkholt’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s finances, accounting, operations, practices or policies. The Company will be initiating a search for a candidate to replace Mr. Bjerkholt as a Chief Financial Officer. Mr. Bjerholt has agreed in principle to continue as a consultant to the Company until December 31, 2017 to assist in an orderly transition.

About SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Recent Trading Information

SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) closed its last trading session 00.00 at 3.89 with 108,411 shares trading hands.